| This week's sponsor is Premier Research. | | | Studying an Addiction Drug? Some Practical Tips To Help
Developing drugs to treat addiction is a complex challenge, and sponsors benefit when they know how addiction trials work. Read our white paper for a closer look. Premier Research. It's what we do. Best. |
Today's Rundown Turnstone Biologics nabs Bristol-Myers R&D exec as new research chief Acorda slumps on safety fears for Parkinson’s drug tozadenant Sanofi, Novo back rare disease startup Inozyme in $49M round [Sponsored] Looking Toward Abuse Deterrent Opioids Genentech doubles down on Arvinas, swelling deal to $650M Germano lands spot on The Medicines Company’s board Acquisitive Quotient buys CDMO Pharmaterials, reveals new identity Featured Story | | | Wednesday, November 15, 2017 Fierce 15 winner Turnstone Biologics has poached Mike Burgess, MBChB, Ph.D., from Bristol-Myers Squibb to be its new head of R&D. Burgess, who had been at BMS as its SVP, head of exploratory clinical and translational research since 2013, has jumped ship to the early-stage startup, which is focused on reviving the fortunes of research into oncolytic viruses and cancer vaccines. |
|
|
| This week's sponsor is Deloitte. | | | |
Top Stories Wednesday, November 15, 2017 Shares in Acorda Therapeutics are on the slide following the news that the company’s Parkinson’s drug tozadenant has been linked to a serious and potentially fatal side effect. Wednesday, November 15, 2017 Using tech licensed from Yale University and with a string of biopharma executives and Big Pharma venture backers, Inozyme Pharma has emerged from stealth with $49 million and a mission. Monday, November 13, 2017 The complex and intertwined dual epidemics of poorly treated pain and opioid addiction require a combined, artful approach to secure the best possible results for patients. Wednesday, November 15, 2017 Genentech has doubled the size of its alliance with Arvinas, moving the potential value of the pact up above $650 million. The expansion of the deal gives the Roche subsidiary the chance to use Arvinas’ protein degradation technology against additional disease targets. Wednesday, November 15, 2017 The Medicines Company has tweaked its board, bringing former Pfizer executive Geno Germano in as an independent director and expanding Fred Eshelman’s role. Germano takes up the position 8 months after a shift in focus at Intrexon led him to give up the president post at the synthetic biology company. Wednesday, November 15, 2017 After two U.S. acquisitions back in February, Quotient Clinical has been renamed as Quotient Sciences, and right after that, made another purchase. | This week's sponsor is Charles River. | | | |
Resources Sponsored by: Reprints Desk SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs. Download the whitepaper to learn more. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Sponsored by: Veeva Systems See the results from one of the largest, most in-depth surveys of clinical data management professionals on data management practices, performance, and challenges. Sponsored by: Veeva Systems Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Sponsored by: ePharmaSolutions As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution. Sponsored by: Ashfield Healthcare December 5, 2017 | 2pm EST / 11am PST Join this webinar to learn methods that maintain and build sales momentum despite turnover. Sponsored by: Veeva CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. BioBasics: Biotech for the Non-Scientist November 30-December 1, 2017 | Boston, MA CBI’s Commercial Data Insights 2017 November 28-29, 2017 | Philadelphia, PA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA FierceBiotech Executive Breakfast: Get Good Science and the Money will Follow January 9, 2018 | San Francisco, CA Register Today – ISPE Biopharmaceutical Manufacturing Conference December 4th-6th, 2017 | San Francisco, CA BIO Asia International Conference March 19-20, 2018 | Tokyo, Japan Molecular Med Tri-Conference February 11-16, 2018 | San Francisco, CA | 